Outlook Therapeutics (OTLK) Competitors $2.03 -0.02 (-0.98%) (As of 12/2/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OTLK vs. MDWD, LFVN, CABA, ZURA, SCPH, PROC, HRTX, TIL, ADAP, and VTYXShould you be buying Outlook Therapeutics stock or one of its competitors? The main competitors of Outlook Therapeutics include MediWound (MDWD), LifeVantage (LFVN), Cabaletta Bio (CABA), Zura Bio (ZURA), scPharmaceuticals (SCPH), Procaps Group (PROC), Heron Therapeutics (HRTX), Instil Bio (TIL), Adaptimmune Therapeutics (ADAP), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical products" industry. Outlook Therapeutics vs. MediWound LifeVantage Cabaletta Bio Zura Bio scPharmaceuticals Procaps Group Heron Therapeutics Instil Bio Adaptimmune Therapeutics Ventyx Biosciences MediWound (NASDAQ:MDWD) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment. Does the media prefer MDWD or OTLK? In the previous week, Outlook Therapeutics had 12 more articles in the media than MediWound. MarketBeat recorded 24 mentions for Outlook Therapeutics and 12 mentions for MediWound. MediWound's average media sentiment score of 0.14 beat Outlook Therapeutics' score of -0.01 indicating that MediWound is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Outlook Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Is MDWD or OTLK more profitable? Outlook Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -142.29%. Outlook Therapeutics' return on equity of 0.00% beat MediWound's return on equity.Company Net Margins Return on Equity Return on Assets MediWound-142.29% -82.17% -33.67% Outlook Therapeutics N/A N/A -160.88% Do analysts prefer MDWD or OTLK? MediWound presently has a consensus target price of $27.50, suggesting a potential upside of 48.81%. Outlook Therapeutics has a consensus target price of $42.34, suggesting a potential upside of 1,985.86%. Given Outlook Therapeutics' higher probable upside, analysts clearly believe Outlook Therapeutics is more favorable than MediWound.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediWound 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has more risk & volatility, MDWD or OTLK? MediWound has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Do insiders & institutionals believe in MDWD or OTLK? 46.8% of MediWound shares are held by institutional investors. Comparatively, 11.2% of Outlook Therapeutics shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 3.4% of Outlook Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer MDWD or OTLK? MediWound received 233 more outperform votes than Outlook Therapeutics when rated by MarketBeat users. However, 70.93% of users gave Outlook Therapeutics an outperform vote while only 62.15% of users gave MediWound an outperform vote. CompanyUnderperformOutperformMediWoundOutperform Votes39462.15% Underperform Votes24037.85% Outlook TherapeuticsOutperform Votes16170.93% Underperform Votes6629.07% Which has higher earnings & valuation, MDWD or OTLK? MediWound has higher revenue and earnings than Outlook Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediWound$19.72M10.11-$6.72M-$2.90-6.37Outlook TherapeuticsN/AN/A-$58.98M-$10.70-0.19 SummaryMediWound beats Outlook Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Porter & CompanyUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOutlook TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.03M$3.05B$5.36B$8.94BDividend YieldN/A1.84%5.33%4.05%P/E Ratio-0.1947.13117.6718.00Price / SalesN/A489.601,424.20155.72Price / CashN/A175.8442.8038.60Price / Book-1.834.967.356.66Net Income-$58.98M-$41.68M$118.46M$224.93M7 Day Performance-58.49%10.83%3.40%2.50%1 Month Performance-66.45%11.26%2.49%10.24%1 Year Performance-78.53%38.03%36.17%30.14% Outlook Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOutlook Therapeutics1.7807 of 5 stars$2.03-1.0%$42.34+1,985.9%-78.5%$48.03MN/A-0.1920Analyst ForecastAnalyst RevisionNews CoverageMDWDMediWound1.6409 of 5 stars$18.10+3.6%$27.50+51.9%+104.5%$195.30M$18.69M-6.0280Analyst RevisionLFVNLifeVantage3.7184 of 5 stars$15.11+3.7%N/A+138.8%$189.18M$200.16M45.66260Positive NewsGap UpCABACabaletta Bio3.4253 of 5 stars$3.82+26.9%$26.25+587.2%-74.2%$186.71MN/A-1.7850High Trading VolumeZURAZura Bio3.243 of 5 stars$2.85-6.6%$15.80+454.4%-41.4%$186.08MN/A0.003SCPHscPharmaceuticals4.0281 of 5 stars$3.71+2.5%$15.00+304.3%-32.4%$185.65M$13.59M-1.9130Positive NewsPROCProcaps Group0.8411 of 5 stars$1.64+8.6%N/A-37.4%$185.03M$414.10M3.275,500Gap UpHRTXHeron Therapeutics4.0401 of 5 stars$1.22+2.1%$5.67+366.4%-7.6%$184.80M$127.04M-6.67300Positive NewsGap UpTILInstil Bio3.6131 of 5 stars$28.28+5.1%$145.00+412.7%+301.5%$184.67MN/A-2.5449Short Interest ↓Positive NewsADAPAdaptimmune Therapeutics2.0723 of 5 stars$0.72-0.1%$2.79+287.2%+33.4%$184.23M$60.28M-3.36449Short Interest ↑VTYXVentyx Biosciences3.4949 of 5 stars$2.56-4.5%$10.00+290.6%+14.5%$181.02MN/A-1.1073Positive News Related Companies and Tools Related Companies MediWound Competitors LifeVantage Competitors Cabaletta Bio Competitors Zura Bio Competitors scPharmaceuticals Competitors Procaps Group Competitors Heron Therapeutics Competitors Instil Bio Competitors Adaptimmune Therapeutics Competitors Ventyx Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OTLK) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OTLK Stock Alerts